+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

A new pill designed to treat active COVID-19 infections was just approved by the UK, the first country to do so

Nov 4, 2021, 19:28 IST
Business Insider
Molnupiravir, the antiviral COVID-19 pill from Merck and Ridgeback Biotherapeutics. Merck
  • The UK on Thursday became the first country to approve Merck's new COVID-19 antiviral, molnupiravir.
  • The pill is the first drug on the market designed specifically to target active COVID-19 infections.
Advertisement

The UK on Thursday became the first country to approve a new antiviral pill designed specifically to treat COVID-19 infections.

The pill, developed by Merck and Ridgeback Biotherapeutics, was found to halve the likelihood of death or hospitalization from COVID-19 during clinical trials.

In a statement early Thursday, Merck said the UK government had ordered 480,000 courses of the drug, molnupiravir, while the US government had ordered 1.7 million courses. Merck is seeking emergency authorization for molnupiravir from the US Food and Drug Administration.

Experts say the drug could prove to be a "game changer" if it can stop people with COVID-19 from becoming very sick. It also has the advantage of being an oral drug, which means you don't need to be in a hospital or clinic to take it.

The UK's approval of the drug is based on results from a recent trial, which tested the pills on 775 adults with mild to moderate COVID-19. Of this group, 7% who received the pill ultimately were hospitalized or died, compared with 14% of those who got a placebo, Merck and Ridgeback said last month.

Advertisement

Analysts are estimating that Merck will make about $22 billion in revenue from selling molnupiravir across the world over the next 10 years. The US has agreed to pay $712 per treatment course, but the cost varies by country.

You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article